Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Published byJob Holland Modified over 5 years ago

Similar presentations

Presentation on theme: "A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie."— Presentation transcript:

1 A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie N Wietzke, Scott A Flanders, and Suman L. Sood Blood Volume 128(22): December 2, 2016 ©2016 by American Society of Hematology

2 Dana E. Angelini et al. Blood 2016;128:1181
©2016 by American Society of Hematology

3 Dana E. Angelini et al. Blood 2016;128:1181
©2016 by American Society of Hematology

4 Dana E. Angelini et al. Blood 2016;128:1181
©2016 by American Society of Hematology

Download ppt "A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie."

Similar presentations

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13):4793-4807 December 15, 2008 ©2008 by American Society of Hematology.

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses by Klaus Juul, Anne Tybjærg-Hansen, Rolf Steffensen, Steen Kofoed, Gorm Jensen, and.

Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses by Klaus Juul, Anne Tybjærg-Hansen, Rolf Steffensen, Steen Kofoed, Gorm Jensen, and.
by Hugoline G. de Haan, Irene D. Bezemer, Carine J. M

by Hugoline G. de Haan, Irene D. Bezemer, Carine J. M
Do HSCs divide asymmetrically?

Do HSCs divide asymmetrically?
Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,

Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,
by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,
TCR-MHC-peptide(s): in vivo veritas

TCR-MHC-peptide(s): in vivo veritas
by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa
Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura
Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study by Lori-Ann Linkins,

Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study by Lori-Ann Linkins,
Next-generation leukemia immunotherapy

Next-generation leukemia immunotherapy
An endothelial metronome breast cancer?

An endothelial metronome breast cancer?
Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11):3909-3918 June 1, 1997 ©1997.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Similar presentations

Ads by Google